See the published version of this preprint at Journal of Clinical Immunology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research Article
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The results and the complications following SARS-CoV2 infection in individuals with primary immunodeficiency(PID) remain unclear. The objective of this study is to report the course, follow-up, outcome of COVID 19 in 26 patients with PIDs from a tertiary PID center in Turkey. Infection mortality rate was found to be %7.69 which is eight times higher than infection mortality rate (%0.97) in general population in Turkey. Although it is clear that mortality in patients with PID is higher than in the normal population, it is difficult to suggest a more risky group among primary immunodeficiencies for COVID-19 with a complicated course according to the data published so far. The groups are quite heterogeneous regarding age, sex and comorbidities, but it is remarkable that patients who underwent HSCT with curative treatment had an uncomplicated course despite comorbidities. Future studies as metaanalysis getting data together may help to get a more reliable conclusion.
Keywords
SARS-CoV2 infection, COVID 19, primary immunodeficiencies, metaanalysis
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Journal of Clinical Immunology.
Version 1
Posted 15 Feb, 2021
No community comments so far
Reviews received
Received 11 Feb, 2021
Reviewers invited
Invitations sent on 10 Feb, 2021
First submitted
On 27 Jan, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Immunology
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Journal of Clinical Immunology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Journal of Clinical Immunology.
Version 1
Posted 15 Feb, 2021
No community comments so far
Reviews received
Received 11 Feb, 2021
Reviewers invited
Invitations sent on 10 Feb, 2021
First submitted
On 27 Jan, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Immunology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Journal of Clinical Immunology.
The results and the complications following SARS-CoV2 infection in individuals with primary immunodeficiency(PID) remain unclear. The objective of this study is to report the course, follow-up, outcome of COVID 19 in 26 patients with PIDs from a tertiary PID center in Turkey. Infection mortality rate was found to be %7.69 which is eight times higher than infection mortality rate (%0.97) in general population in Turkey. Although it is clear that mortality in patients with PID is higher than in the normal population, it is difficult to suggest a more risky group among primary immunodeficiencies for COVID-19 with a complicated course according to the data published so far. The groups are quite heterogeneous regarding age, sex and comorbidities, but it is remarkable that patients who underwent HSCT with curative treatment had an uncomplicated course despite comorbidities. Future studies as metaanalysis getting data together may help to get a more reliable conclusion.
Figure 1
Loading...